Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases

Table 4 ORs (95% CIs) for a 30% baseline biomarker increment, from analyses that combine trials and treatment arms in the WHI postmenopausal HT trials, with biomarkers simultaneously modeled

Baseline biomarker	CHD^a	Baseline biomarker	Stroke^a
B2M	1.19 (1.05, 1.35)^b,c	B2M	1.11 (0.96, 1.29)^b
ORM1	1.06 (0.93, 1.22)	IGFBP2	1.08 (1.00, 1.17)^c
THBS1	0.96 (0.92, 0.99)^c	IGFBP4	1.17 (1.04, 1.32)^c
CFD	1.09 (0.93, 1.28)	IGFBP6	0.97 (0.89, 1.05)
IGFBP1	1.01 (0.96, 1.06)	HPX	1.08 (0.92, 1.26)
Treatment^d	1.28 (0.91, 1.82)	Treatment^b	1.71 (1.21, 2.42)
Trial^d	1.00 (0.70, 1.44)	Trial^b	1.08 (0.76, 1.53)

^aCHD analyses based on 596 combined cases and controls; stroke analyses based on 620 combined cases and controls.
^bAll analyses include baseline age, prior history of study disease, systolic and diastolic blood pressure, smoking history, treated diabetes history, prior HT use, and body mass index as regression variables to control confounding.
^cSignificant at P = 0.05.
^dTreatment, 1 - active; 0 - placebo; Trial, 1 - E + P trial (no hysterectomy), 0 - E-alone trial (post-hysterectomy).

ISSN: 1756-994X